Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Return on Capital Employed (2016 - 2025)

Northwest Biotherapeutics' Return on Capital Employed history spans 15 years, with the latest figure at 0.37% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.37% for Q4 2025, down 7.0% from a year ago — trailing twelve months through Dec 2025 was 0.37% (down 7.0% YoY), and the annual figure for FY2025 was 0.35%, down 8.0%.
  • Return on Capital Employed for Q4 2025 was 0.37% at Northwest Biotherapeutics, up from 0.28% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 6.51% in Q2 2023 to a low of 2.34% in Q3 2023.
  • The 5-year median for Return on Capital Employed is 0.5% (2022), against an average of 1.24%.
  • The sharpest move saw Return on Capital Employed skyrocketed 573bps in 2023, then plummeted -427bps in 2024.
  • Year by year, Return on Capital Employed stood at 0.53% in 2021, then surged by 34bps to 0.71% in 2022, then skyrocketed by 404bps to 3.58% in 2023, then plummeted by -88bps to 0.44% in 2024, then dropped by -16bps to 0.37% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.37%, 0.28%, and 0.3% for Q4 2025, Q3 2025, and Q2 2025 respectively.